Nationwide, Pragmatic, Direct-to-Patient Primary Aldosteronism Testing Program.

Hypertension

Division of Endocrinology, Diabetes, and Hypertension, Center for Adrenal Disorders (J.M.B., L.C.T., E.E.A., A.F., A.E.M., Y.M.N., B.B., B.H., J.M., K.F., A.J.N., W.W.P., A.V.), Harvard Medical School, Boston, MA.

Published: June 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Primary aldosteronism, an endocrinopathy present in ≥10% to 25% of patients with hypertension, confers excess cardiovascular risk that can be mitigated with aldosterone-directed therapy. However, only 2% of eligible patients undergo guideline-recommended screening. This study aimed to bypass clinical inertia and identify people with primary aldosteronism using pragmatic, direct-to-patient testing.

Methods: Hypertensive adults were recruited via online platforms and underwent virtual consent and local phlebotomy. Using a standardized diagnostic algorithm, laboratory results with interpretations were communicated to patients and primary care providers. Follow-up was ascertained at 6 to 12 months. The primary outcome was the frequency of a positive test for primary aldosteronism. Secondary outcomes included follow-up primary aldosteronism testing and implementation of aldosterone-targeted therapies.

Results: The study population (N=694) had a mean age of 63.3±11.3 years, was 52.2% female, and hailed from 41 US states. Overall, 25.4% had a positive test for primary aldosteronism. Sleep apnea, resistant hypertension, and hypokalemia were the most common testing indications, with 55.2% of participants having ≥2 indications. Over half of participants (57%) were already under endocrinology, cardiology, or nephrology care, yet had not been tested. In longitudinal follow-up of participants with a positive result, 25.5% had additional testing, 13.7% were started on aldosterone-targeted therapy (mineralocorticoid receptor antagonist or adrenalectomy), and 24.5% reported improved blood pressure control.

Conclusions: Pragmatic, direct-to-patient testing, and simplified results interpretation is a feasible, scalable method to increase primary aldosteronism diagnoses and implementation of aldosterone-targeted therapies. Given that new hypertension guidelines recommend primary aldosteronism screening in all hypertensive people, practical approaches to test, interpret, and implement results will be essential.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078016PMC
http://dx.doi.org/10.1161/HYPERTENSIONAHA.125.24648DOI Listing

Publication Analysis

Top Keywords

primary aldosteronism
32
pragmatic direct-to-patient
12
primary
10
aldosteronism
8
aldosteronism testing
8
positive test
8
test primary
8
implementation aldosterone-targeted
8
testing
5
nationwide pragmatic
4

Similar Publications

Aldosterone is synthesized by the CYP11B2 enzyme, primarily in the zona glomerulosa of the adrenal gland. It exerts its classical effects on sodium and water balance in the renal distal nephron through binding to the mineralocorticoid receptor (MR). Excess aldosterone production or overactivation of the MR outside the distal nephron leads to cardiac, renal, and vascular injury by increasing oxidative stress and activating the inflammatory and fibrotic pathways.

View Article and Find Full Text PDF

[Paraneoplastic rhabdomyolysis].

Inn Med (Heidelb)

September 2025

Klinik für Allgemeine Innere Medizin und Altersmedizin, Evangelisches Klinikum Köln Weyertal, Weyertal 76, 50931, Köln, Deutschland.

A 49-year-old female patient presented with decline of general health and muscle pain. Laboratory findings showed a combination of rhabdomyolysis and severe hypokalemia. Symptoms improved with potassium supplementation.

View Article and Find Full Text PDF

Context: Although salivary steroid sampling offers several advantages, the diagnostic potential of salivary steroid metabolites remains largely unexplored.Objective To evaluate the diagnostic utility of salivary steroid profiling in patients with adrenal diseases.

Design: Prospective multicenter study.

View Article and Find Full Text PDF

Primary Aldosteronism: Ubiquitous, Yet Unrecognized.

J Am Coll Cardiol

August 2025

Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address:

View Article and Find Full Text PDF

Rethinking Primary Aldosteronism: The 2025 John H. Laragh Research Award.

Am J Hypertens

September 2025

Department of Medicine, Division of Endocrinology and Metabolism, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Dr John Laragh, a pioneer in the field of hypertension, held a fundamental belief in the need to challenge existing dogmas in medicine to enhance our scientific understanding of disease and advance patient care. Perhaps in no area of hypertension does this ring truer with than primary aldosteronism (PA). Following its initial description in the mid-1950s with an initial surge in diagnoses soon thereafter, PA was ultimately relegated to be considered a "zebra" of hypertension felt to be responsible for only a small percentage of cases.

View Article and Find Full Text PDF